A health ministry panel has delayed giving a stamp of approval to Shionogi’s COVID-19 anti-viral pill, concluding that it needs more data before making a judgment on its efficacy.
The delay is a blow to one of Japan’s largest drugmakers and also raises questions about the process for drugs to gain fast-track approvals in times of emergency.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.